APA (7th ed.) Citation

Pio Lopez, Lulu Bravo, Erik Buntinx, Charissa Borja-Tabora, Hector Velasquez, Edith Johana Rodriquez, . . . Igor Smolenov. (2023). Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Pio Lopez, et al. Safety and Immunogenicity of SCB-2019, an Adjuvanted, Recombinant SARS-CoV-2 Trimeric S-protein Subunit COVID-19 Vaccine in Healthy 12-17 Year-old Adolescents. Taylor & Francis Group, 2023.

MLA (9th ed.) Citation

Pio Lopez, et al. Safety and Immunogenicity of SCB-2019, an Adjuvanted, Recombinant SARS-CoV-2 Trimeric S-protein Subunit COVID-19 Vaccine in Healthy 12-17 Year-old Adolescents. Taylor & Francis Group, 2023.